CLSPN and cancer: This body of work not only furthers our understanding of the molecular relationship between Chk1 and NF-κB and how defects in the Claspin–Chk1 signaling pathway promote disease etiology, but also how drug resistance influences cancer evolution and offers clinicians important biomarkers for disease resistance.